News
Read our latest SpOTLight newsletter for a digest of OTL news:
-
SPOTLIGHT October 2023
Featured: Discussing the Promise and Future of RNA Medicines with Dr. Howard Chang
October 12, 2023
Read additional news about OTL, our licensees, and Stanford technologies:
-
NextVivo Launches from Khosla Ventures to Transform Drug Development Using Next-Generation Organoid Platform
Company Raises $7.9 Million in Financing led by Khosla Ventures with participation from Alexandria Venture Investments, Wilson Sonsini, and individual investors.
December 09, 2021
-
National Academy of Inventors Announces 2021 Fellows
The National Academy of Inventors (NAI) has elected 164 prolific academic innovators from across the world to NAI Fellow status.
December 07, 2021
-
November 11, 2021
-
SPOTLIGHT November 2021
A New Normal: Digital Health in the Post-COVID Era
November 01, 2021
-
SPOTLIGHT September 2021
Thinking Ahead: Three Stanford Researchers on the State of Neuroscience
September 01, 2021
-
August 31, 2021
-
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
Research collaborations initiated with MUSC Foundation for Research Development, SU and the U of Pittsburgh to identify and advance therapies for genetic diseases and cancers.
July 08, 2021
-
June 24, 2021
-
Evonik and Stanford University Sign Research Collaboration: Evonik to Market and Develop New Drug Delivery Platform for mRNA and Gene Therapy
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs).
June 10, 2021
-
June 10, 2021
-
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
Through Stanford’s Innovative Medicines Accelerator (IMA), its researchers will be able to access Twist’s “Library of Libraries.”
April 07, 2021
-
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Total of $195 million raised to date. | The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors.
March 15, 2021
-
OTL's First 50 Years: An Executive Roundtable
Since its founding 50 years ago, only three executive directors have helmed Stanford’s tech transfer office. They sit down to talk leadership, “secret sauces,” and mission.
February 25, 2021
-
SPOTLIGHT February 2021
OTL's First 50 Years and Beyond
February 25, 2021
-
DiCE Gets Its 'Library' Card Ready As It Speeds Development Of DNA Database-derived Molecules with More Investor Cash
The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.
January 08, 2021
-
Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease
IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene therapy to restore normal hemoglobin expression
December 14, 2020
-
Top US, UK, and EU Universities Working Together to Help Economies Fuel Post-COVID Recovery
Ten leading US, UK, & EU universities discuss with govt. leaders and funding bodies how to harness the enormous potential of research and commercialization for COVID-19 recovery.
September 18, 2020
-
A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout
Debanjan Ray apparently had big plans when he quietly left his long-held CFO spot at CytomX back in March 2019. He had gotten his own biotech.
September 17, 2020
-
Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation
Palleon Pharmaceuticals announced the completion of a $100 million Series B round to develop its pipeline of glyco-immunology therapies.
September 17, 2020
-
Graphite Bio Launches with $45 Million Series A Financing
Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital
September 16, 2020